$ATLO

Ames National Corporation (ATLO) to Issue Quarterly Dividend of $0.24 on June 15th

Ames National Corporation (NASDAQ:ATLO) declared a quarterly dividend of $0.24 per share, payable June 15 to shareholders of record June 1 (ex-dividend June 1), according to the company. The article cites an annualized dividend yield of about 3.3%. It also notes Q1 results: $0.67 EPS on $18.22 million revenue, with analysts projecting $2.7 EPS for the fiscal year.

Original reporting
Published May 30, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ames National Corporation (ATLO) to Issue Quarterly Dividend of $0.24 on June 15th — source image
Decision brief

The 30-second read

$ATLOBullishMed
01

Why it matters

The main tradable element is the calendar (record/ex-dividend/payment). Without new earnings or guidance, the impact should be incremental.

02

Market read

Near-term income-catalyst around ex-dividend/record-date; limited fundamental information beyond payout amount.

03

What to watch

Watch for whether the dividend is sustainable versus earnings power; the article cites a flat 3-year average change, suggesting limited signal on trajectory.

Relevance 6/10Novelty 7/10Timing: Ex-dividend date June 1; payment June 15

Background

Dividend declarations for small community banks often matter most for income investors and around ex-dividend timing rather than for fundamental repricing.

Company-level read

Ticker impact

$ATLOBullishMedium confidence
Context

Ames National declared a quarterly dividend of $0.24/share with record date June 1 and payment date June 15, setting a near-term cash-return catalyst.

Expected impact

Likely modest, short-lived support around ex-dividend/record-date mechanics; limited upside absent new operating information.

Evidence & confidence

The article provides a concrete dividend amount and dates, but no new guidance, balance-sheet change, or earnings revision.

Market effects

Reinforces typical community-bank shareholder-return behavior; limited read-across without sector-wide rate/credit news.

Local Iowa community bank dividend may modestly support retail/income sentiment but with small market-cap scale.

Low—single-company corporate action with no cross-border linkage.

Counterpoint

Dividend yield (~3.3%) may attract buyers, but if the payout is flat, it may not offset any underlying credit/rate risk concerns.

Key entities

  • Ames National Corporation

    Declared a quarterly dividend of $0.24/share; record date June 1 and payment June 15.

Related articles

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$BAMedAI 8/10

Boeing’s MAX 10 Schedule Puts 27 United Planes Beyond 2027 as Labor Tensions Rise

Boeing's MAX 10 delays push 27 United Airlines jets to post-2027 delivery, per United's latest filing. Boeing completed flight tests but awaits certification. BA shares fell 7.5% last week, erasing $13.8B in market cap. Labor tensions rise as Boeing engineers reject contract offers, risking a strike. Boeing's Q2 revenue rose 8% to $24.56B, with a $715B backlog. Analysts maintain a positive outlook, with a consensus price target of $274.85.

$TEVAMed

Teva share price hits nearly 10-year high

Teva Pharmaceutical (TEVA) reached a nearly 10-year high, with shares up 1.44% on Friday, giving a $43.51B market cap. The company reported strong Q2 results, raised annual revenue guidance, and received debt rating upgrades from Moody's and Fitch. The FDA accepted its Ecopipam drug application. Analysts have an average price target of $42.38, a 12.3% premium to current levels.

$NVDAHighAI 8/10

Nvidia’s 15% Price Hike Reveals the Hidden Cost of the AI Boom

Nvidia (NVDA) is raising AI server prices by over 15% due to a doubling in server DRAM costs in Q1 2026, with memory now representing 25% of high-end rack costs. Apple (AAPL) and Amazon (AMZN) have also raised prices, citing memory cost spikes. Deloitte projects AI-server DRAM prices to quadruple in 2026, with shortages expected to persist through 2027. Memory suppliers like Micron (MU), SK Hynix (SKHY), and Samsung are gaining pricing power.